BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional …

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, today announced the release of the enhanced LifeMap BioReagents portal (http://bioreagents.lifemapsc.com/) featuring an improved user interface, product descriptions, and customer support options, as well as the addition of new PureStem progenitor cells to the site. These novel progenitors provide new and unique tools for researchers to study developmental biology, tissue genesis and regenerative medicine, demonstrating purity in culture and unique gene expression. Among the new product offerings are novel PureStem progenitor cells such as the E72 cells capable of differentiating into betatrophin-expressing adipocytes, which may be useful in diabetes research.

Via LifeMap BioReagents, researchers in academia, research hospitals, and biotech and pharma companies can access and purchase BioTimes research products, including PureStem human progenitor cells, PureStem packages, clinical and research grade human embryonic stem cell (hES) lines, culture media, and cell differentiation kits. As of April, the portal also offers select recombinant proteins, including growth factors, signaling molecules, differentiation factors, cytokines and chemokines that complement BioTimeresearch product lines.

LifeMap BioReagents is integrated with LifeMaps integrated database suite products LifeMap Discovery, GeneCards and MalaCards, thereby providing all biomedical researchers accessing these databases a means of identifying stem cell reagents that can enhance research and discovery efforts in a variety of fields, including stem cell research, developmental biology, mechanisms of various human diseases, drug discovery and therapeutic discovery and development. According to Google Analytics, the sites have generated more than 2,000,000 unique visitors with more than 13,000,000 page views in the past 12 months. LifeMap holds an exclusive, worldwide license from Yeda Research and Development Company Ltd., the commercial arm of theWeizmann Institute of Science, to marketGeneCards(www.genecards.org), the human gene compendium, andMalaCards(www.malacards.org), a database with nearly 17,000 human disease entries.

The diversity, purity, and scalability of PureStem cells combined with the continued discovery process underway at BioTime, where novel differentiation pathways are being defined, gives us a growing opportunity to market these products in the research sector, said Jeffrey Janus, Vice President of Sales and Marketing at BioTime. This is an exciting beginning to a new era in stem cell research. In combination with the LifeMap integrated database suite, our embryonic progenitors will provide researchers a unique new set of products to make novel clinical discoveries and advance the field of regenerative medicine.

We are pleased to continue the expansion and enhancement of our e-Commerce portal, statedYaron Guan-Golan, Head of Marketing at LifeMap Sciences. Our growing user base will have improved access to our product portfolio via LifeMap BioReagents. The addition of PureStem human progenitor lines, including cell types targeting the hottest new research in diabetes, will increase LifeMap BioReagents brand awareness and the quality of our offering to the global biomedical research community.

About LifeMap Sciences, Inc.

LifeMap Sciences (www.lifemapsc.com) core technology and business is based on its integrated database suite, the discovery platform for biomedical and stem cell research. This platform includes GeneCards, the leading human gene database; LifeMap Discovery, the database of embryonic development, stem cell research and regenerative medicine; and MalaCards, the human disease database. According to Google Analytics, the sites have generated more than 2,000,000 unique visitors with more than 13,000,000 page views in the past 12 months. LifeMap Sciences also markets PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTimes principal marketing subsidiary for research products, including PureStem human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan growth media for progenitor cell lines, and cell differentiation media for non-therapeutic uses, via its LifeMap BioReagents portal. LifeMap Sciences utilizes its databases as part of its online marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMaps scientists utilize LifeMaps proprietary platform, including LifeMap Discovery, its stem cell database along with the GeneCards and MalaCards integrated database suite, to aid in the development of BioTimes proprietary PureStem human progenitor cell lines into products for the treatment of human diseases, especially degenerative diseases that might be treatable with cell replacement therapies. The LifeMap Discovery platform will be used to select the progenitor cell lines that are most likely to be useful in developing cell-based regenerative medicine therapies for a wide range of diseases.

See original here:
BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional ...